Xyotax Fast Tracked for Advanced NSCLC in Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 3
Volume 15
Issue 3

Cell Therapeutics' Xyotax (paclitaxel poliglumex), a biologically enhanced chemotherapeutic that links paclitaxel to a biodegradable polyglutamate polymer, has gained fast track status from the FDA for the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in women with poor performance status.

SEATTLE—Cell Therapeutics' Xyotax (paclitaxel poliglumex), a biologically enhanced chemotherapeutic that links paclitaxel to a biodegradable polyglutamate polymer, has gained fast track status from the FDA for the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in women with poor performance status. A pooled analysis from three studies showed that women treated with Xyotax plus carboplatin had a 39% probability of living at least 1 year, compared with 25% for men. Clinical studies support that metabolism of Xyotax may be influenced by estrogen, thus leading to enhanced efficacy in women with lung cancer. The phase III PIONEER trial is evaluating Xyotax in this setting in women at 170 sites.

Articles in this issue
FDA Approves Eraxis to Treat Candidemia
NeoGuide's New Colonoscopy System Addresses ‘Looping'
New Budget Plan Cuts NCI Funding by 0.8% for FY 2007
Lilly Oncology on Canvas Invites Entries
Shorter FEC + Pac Ups DFS in Breast Ca
Xyotax Fast Tracked for Advanced NSCLC in Women
FDA Guidances for Early Human Testing of New Drugs
Zactima Gets Fast Track Status for Medullary Thyroid Cancer
Darbepoetin During RT Boosts Hb Level, With QOL Benefit
Breast, Colorectal Cancer Care Quality 'Excellent'
Dose-Dense Adjuvant Chemo Validated in Breast Cancer
Some Complete Molecular Responses Seen With CML Vaccine
HCT Provides Long-Term Survival in CML
Rituxan + CHOP Approved for Diffuse Large B Cell NHL
Inpatient Hem/Onc Unit Adds Phase I Clinical Trial Program
Recent Videos
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
Related Content
Expert teams debate cutting-edge lung cancer treatments, exploring trial data and innovative strategies for improving patient outcomes in NSCLC and SCLC.

The Differing Opinions of Lung Cancer Care: The Phantoms vs The Accelerators

ONCOLOGY Staff
December 13th 2025
Article

Expert teams debate cutting-edge lung cancer treatments, exploring trial data and innovative strategies for improving patient outcomes in NSCLC and SCLC.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC

Russ Conroy
November 8th 2025
Article

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.